We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Serum Biomarker Investigated for Early Gastric Cancer Diagnosis

By LabMedica International staff writers
Posted on 03 Nov 2021
Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide. More...
More importantly, most reported GC cases are in developing countries. The high mortality of GC is often due to its nonspecific symptoms and delayed diagnosis.

Early detection is key step in the management of patients and survival improvement. Gastric endoscopy is widely used for GC screening. Magnifying endoscopy (ME) with narrow band imaging (ME-NBI) is also an effective tool for real-time endoscopic diagnosis of early gastric cancer (EGC). However, using these tools, identifying subtle lesions or differentiation between inflammation and early intraepithelial neoplasia is still challenging.

Gastroenterologists at the Shanghai General Hospital (Shanghai, China) enrolled a total of 108 patients who presented with GC between July 2016 and June 2018. The subjects included 38 cases of EGC and 70 cases of advanced gastric cancer (AGC). Also included were 28 patients with low-grade intraepithelial neoplasia (LGN, precancerous group), 37 patients with chronic superficial gastritis (CSG) associated with Helicobacter pylori infection (Hpi), 49 patients with other system malignant tumors (OST) and 178 healthy volunteers (healthy control, HC).

Serum samples from 20 patients with EGC and 20 HCs were selected for polypeptide analysis via mass spectrometry. A nanoliter flow HPLC system, EASY-nLC 1000, with a trap column and a C18 column was used in this study and the analysis was performed using the Orbitrap Elite system (Thermo Scientific, Waltham, MA, USA). To confirm the mass spectrometry results, serum samples from 16 patients with EGC, 16 patients with AGC, and 16 HCs were subjected to immunoblotting against inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4).

The tumor tissues of 20 patients with GC and their adjacent normal tissues were embedded, sectioned, and placed in Leica Bond-Max automatic immunohistochemical machine (Leica Microsystems, Berlin, Germany). The expression profiles of ITIH4 in 312 serum samples, including 26 EGC, 48 AGC, 26 LGN, 37 Hpi, 49 OST, and 126 HC serum samples, were determined using enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA). To determine the expression levels of target molecules in blood, exosomes in serum samples were isolated, identified, and analyzed.

The investigators reported that ITIH4 was identified as a key biomarker in patients with EGC. Its expression level in serum from the EGC group, which showed the highest specificity (94.5%), was significantly higher than those in sera from other GC groups as well as the control. Western blot analysis, immunohistochemical staining, and exosome analysis also confirmed ITIH4 expression in sera from patients with GC, but not in those from healthy individual.

The authors concluded that the serum ITIH4 expression level is a promising biomarker for the early diagnosis of GC. ITIH4 levels in serum samples from patients at the early stage of GC were significantly higher than those in serum samples from patients with GC at the advanced stage or HCs. This finding indicated that serum ITIH4 levels can be a potential biomarker for early stage GC diagnosis. The study was published on October 20, 2021 on the journal Clinica Chimica Acta.

Related Links:
Shanghai General Hospital
Thermo Scientific
Leica Microsystems
R&D Systems



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.